Coley begins Phase I/II

Coley Pharmaceutical Group (Wellesley, Mass.) began the first of three Phase I/II trials of its CpG 7909 CpG DNA-based immune stimulant to treat cancer. The U.S. trial will treat 24 patients with rela...